Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04957329 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Effect of Benzalkonium Chloride Preserved and Preservative-free Latanoprost Eye Drops on Conjunctival Goblet Cells

StatusRecruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date: Aug 1, 2023 to Dec 31, 2026
    • Study completion date: Mar 31, 2024 to Dec 31, 2026
    v4
  2. Study completion date: Oct 28, 2023 to Mar 31, 2024
    • Eligibility criteria shortened, about 16 words
    v3
  3. Trial status: Not Yet Recruiting to Recruitingv2 Show 5 more changesShow less
    • Primary completion date: Dec 1, 2022 to Aug 1, 2023
    • Primary endpoint revised
    • Study completion date: Feb 28, 2023 to Oct 28, 2023
    • Secondary endpoints revised (5)
    • Site details revised at 2 of 2 sites
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
a randomized, investigator-blind, interventinal study will compare the effect of benzalkonium-chloride (BAK) preserved and preservative-free (PF) eye drops on conjunctival goblet cells.
Trial Details
NCT Number NCT04957329
Lead Sponsor Copenhagen University Hospital, Rigshospitalet
Collaborators: Laboratoires Thea
Conditions
(from sponsor)		 Glaucoma, Ocular Hypertension
Related terms Glaucoma, Ocular Hypertension
Enrollment 28 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov